Plunkett Research Online: Adamas Pharmaceuticals Inc

ADAMAS PHARMACEUTICALS INC (ADMS:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company’s approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease. It operates in one reportable segme.....



Adamas Pharmaceuticals Inc
Ticker: ADMS
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 510 450-3500
Fax: 510 428-0519
Address: 1900 Powell Street
Suite 750
Emeryville, CA 94608 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
ContactsDescription
Alfred MerriweatherCFO
Christopher PrentissChief Accounting Officer
See More
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company’s approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease. It operates in one reportable segme.....See More See More

Auditor: PricewaterhouseCoopers LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015201420132012
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: